湿热因素对PNS临床病情的影响及肾综湿热证蛋白质组学研究
|
摘要
目的:本课题选择原发性肾病综合征湿热证为对象,先系统研究湿热因素对肾病综合征临床病情的影响,全面了解湿热因素对肾病综合征影响的重点环节,为指导肾病综合征临床治疗,提高临床疗效提供理论依据。再进行原发性肾病综合征湿热证的蛋白质组学研究,希望通过对肾病综合征湿热证的蛋白质组学研究,可能会发现特异蛋白。通过对特异蛋白的相关蛋白的分析,能够揭示中医肾病综合征湿热证的实质及湿热致病机理。
方法:本课题主要采用横断面、前瞻、回顾性调查研究方法。通过调查收集符合纳入标准的原发性肾病综合征病例的一般情况、症状、体征、以及部分实验室检查指标,利用SPSS统计软件进行统计分析,全面系统分析湿热因素对原发性肾病综合征病程、病情、复发、实验室指标、疗效等影响。再采用最前沿的蛋白质组学方法,对原发性肾病综合征湿热证与非湿热证及健康对照组利用双向电泳进行差异蛋白分析,再利用质谱技术进行差异蛋白的鉴定。探讨原发性肾病综合征湿热证的分子机制,研究湿热证的本质。
结果:
(一)湿热因素对原发性肾病综合征临床病情的影响
本研究入选病例共120例,根据中医辨证分为湿热证组60例,非湿热证组60例。对两组病例的一般情况、症状、体征、实验室指标、疗效等进行分析比较,全面系统分析湿热因素对原发性肾病综合征病程、病情、复发、实验室指标、疗效等影响。结果如下:
1、一般资料分析湿热证组60例,其中男性47例,女性13例,年龄28.77±16.13岁;非湿热证组60例,其中男性为39例,女性为21例,年龄26.72±15.93岁;经统计学检验,两组在性别、年龄等方面无统计学差异(P＞0.05)。
2、湿热对原发性肾病综合征患者住院时间的影响湿热证组平均住院天数为23.90±11.75天,非湿热证组平均住院天数为16.00±7.47天,湿热证原发性肾病综合征患者住院时间明显长于非湿热证患者。经统计学检验,有统计学意义(P＜0.05)。
3、湿热对原发性肾病综合征患者病程的影响湿热证组平均病程为42.13±46.49月,非湿热证组平均为29.18±29.27月,湿热证原发性肾病综合征患者病程明显长于非湿热证患者。经统计学检验,有统计学意义(P＜0.05)。
4、湿热与伴发感染的关系湿热证组与非湿热证组感染情况比较,湿热证组伴发感染比例(38.3%)叫显高于非湿热证组(16.7%),经统计学检验后,有显著性差异(P＜0.01)。其中湿热证组伴有呼吸系感染者11(47.8%)例,泌尿系感染者5(21.7%)例,胃肠道感染4(17.4%)例,其他3(13.1%)例;非湿热证组伴有呼吸系感染者5(50.0%)例,泌尿系感染者3(30.0%)例,胃肠道感染1(10.0%)例,其他1(10.0%)例。两组在感染类别情况中并无差异,经统计学检验,无统计学意义(P＞0.05)。
5、湿热因素对肾病综合征病情复发的影响湿热证组与非湿热证组复发率比较,原发性肾病综合征湿热证组的复发率(65.0%)明显高于非湿热证组复发率(46.7%),经统计学检验后,有统计学意义(P＜0.05)
6、湿热对临床实验室指标的影响湿热证组与非湿热证组实验室指标比较中,湿热证组血白细胞总数(11.33±6.51*10e9/L)明显高于非湿热证血白细胞总数(8.77±4.50*10e9/L);湿热证组血清总胆固醇(10.99±4.00mmol/L)亦高于非湿热证组(8.19±2.53 mmol/L):湿热证组24小时尿蛋白定量(7.74±4.42 g/24h)大于非湿热证组(5.05±3.55 g/24h)。经统计学检验后,有统计学意义(P＜0.05)。而其他指标比较虽在数值上有一定的差异,但经统计学检验,并无统计学意义(P＞0.05)。
7、湿热与病理类型的关系在收集的120例肾病综合征病例中有39例有病理报告,占总病例的32.5%,其中湿热证组20例,非湿热证组19例。湿热证组病理类型中:微小病变肾病6例(30%);系膜增生性肾炎5例(25.0%);局灶性节段性肾小球硬化0例(0.0%);膜性肾病8例(40.0%);系膜毛细血管性肾小球肾炎1例(5.0%)。非湿热证组病理类型中:微小病变肾病4例(21.1%);系膜增生性肾炎10例(52.6%);局灶性节段性肾小球硬化3例(15.8%);膜性肾病2例10.5%);系膜毛细血管性肾小球肾炎0例(0.0%)。结果显示:原发性肾病综合征湿热证组病理类型中的膜性肾病明显多于非湿热证组,经统计学检验后,有统计学意义(P＜0.05),其它类型比较无明显差异,无统计学意义(P＞0.05)。
8、湿热对疗效的影响湿热证组完全缓解19例(31.7%),显著缓解12例(20.0%),部分缓解10例(16.7%),无效19例(31.7%),总有效率68.3%。非湿热证组完全缓解24例(40.0%),显著缓解17例(28.3%),部分缓解9例(15.0%),无效10例(16.7%),总有效率83.3%。可见湿热证组有效率明显低于非湿热证组。采用等级资料的秩和检验统计分析,有统计学意义(P＜0.05)。
(二)原发性肾病综合征湿热证的蛋白质组学研究
在蛋白质组学研究中,选取5例正常对照组、10例原发性肾病综合征湿热证组和10例非湿热证组进行血清双向凝胶电泳和质谱分析。实验结果:图像清晰,没有背景条纹的干扰,蛋白质斑点分离完全,在相同条件下,反复3次重复的实验结果图大致相同,三组图谱图象分析后平均检测到1108个蛋白质斑点。选取正常对照组图谱作为参考胶,其它两组胶与参考胶匹配,使各凝胶中的蛋白质斑点与参考胶中的对应起来,与参考胶中同一蛋白质斑点相匹配的点为同一种蛋白质。匹配结果显示三组胶蛋白质斑点匹配百分率约为80.12%。
用PDQuest软件将正常对照组、肾病综合征湿热证组和肾病综合征非湿热证组凝胶图像进行定性定量差异表达分析。结合肉眼分辨,我们发现有19个蛋白质斑点在三组凝胶中有显著差异表达。结合软件分析和手工筛选,我们从表达差异蛋白质点中选取6个点清晰且表达水平改变明显的蛋白质点作为最终质谱鉴定的对象。鉴定的结果为:2号蛋白为载脂蛋白C-Ⅲ(Apolipoprotein C-Ⅲ);5号蛋白为α_2-HS-糖蛋白(Alpha-2-HS-glycoprotein);8号蛋白为免疫球蛋白轻链k(Immunoglobulin kappa1-5);10号蛋白为间α-胰蛋白酶抑制因子重链的H2(Inter-alpha-trypsin inhibitor heavy chain H2);15号蛋白为α_1-抗胰蛋白酶(Isoform 1 of Alpha-1-antitrypsin);16号蛋白为血清转铁蛋白(Serotransferrin)。结合临床和蛋白质功能分析,其中载脂蛋白C-Ⅲ和α_2-HS-糖蛋白可作为原发性肾病综合征湿热证的特异表达蛋白,涉及功能主要与脂蛋白代谢、抗炎、抗胰岛素等有关。
结论:
1、由湿热与肾病综合征感染并发症、复发研究的资料分析提示:湿热是引起肾病综合征病情复发的重要因素。
2、由湿热与肾病综合征病程、住院时间、血脂、尿蛋白、疗效等资料分析提示:湿热是引起肾病综合征病情加重、迁延、难治的重要原因。
3、通过对健康对照组和原发性肾病综合征湿热证组及非湿热证组的血清蛋白银染2-DE图谱分析,我们发现确实存在差异表达蛋白。
4、通过对差异蛋白的鉴定分析,初步认为载脂蛋白C-Ⅲ和α_2-HS-糖蛋白可作为原发性肾病综合征湿热证的特异表达蛋白,涉及功能主要与脂蛋白代谢、抗炎、抗胰岛素等有关。
Objective:To guide clinical treatment of nephrotic syndrome,it was started with primary nephrotic Damp-heat and the first systematic research on the nephrotic syndrome of the impact of clinical conditions which is a comprehensive understanding of heat nephrotic syndrome on the impact of key links.With the purpous of further research in damp-heat syndrome with primary nephrotic syndrome and the possibility of the discovery of that specific protein,we analyzed the specific protein that could reveal the damp-heat syndrome of TCM nephrotic syndrome and the pathogenesis of the connotation.
Methods:To explore the molecular mechanism of Primary nephrotic syndrome Damp-heat,and the nature of Damp-heat.It was worked in the methods of cross-section,forward-looking and retrospective survey.To standard in line with the primary nephrotic syndrome,we investgated the patients in general,symptoms,signs,and some indicators of laboratory tests by using SPSS statistical software for statistical analysis to explore the Damp-heat factor in the onset primary nephrotic syndrome and the role in the course of its relevance.Systematically-analyzed the effects of the Damp-heat factors in each course of disease,condition, relapse,laboratory indicators,efficacy,etc.This study use the most cutting-edge proteomics approach,with primary nephrotic syndrome of damp-heat syndrome with non-heat Syndrome and healthy controls for differences in the use of two-dimensional gel electrophoresis protein analysis,and then carried out using mass spectrometry to identify protein differences.
Result:
(一) The impact of Damp-heat on the clinical condition of Primary nephrotic syndrome
In this study,a total of 120 cases of selected cases,including 60 cases of Damp-heat syndrome group and 60 cases of non Damp-heat syndrome group.Through analyzed and compared between the two groups in general, symptoms,signs,laboratory indicators,effects,this study systematically analysis the effects of the Damp-heat factor in the Drimary nephrotic syndrome patient's course of disease,condition,relapse, laboratory indicators,efficacy,etc.The results are as follows.
1.General data analysis
There are 60 cases of Damp-heat syndrome group,Including 47 males and 13 females,and their average age is 28.77±16.13 years old.There are 60 cases of non Damp-heat syndrome group,Including 39 males and 21 females,and their average age is 26.72±15.93 years old.By statistical testing,there is not significant difference between the two groups in gender,age and so on(P＞0.05).
2.The impact of Damp-heat on the days staying in hospital of PNS patients
The average days staying in hospital of Damp-heat syndrome group are 23.90±11.75 days;and the average days staying in hospital of non Damp-heat syndrome group are 16.00±7.47 days.The days staying in hospital of primary nephrotic syndrome Damp-heat syndrome group are significantly longer than the non Damp-heat syndrome group.By statistical testing,there is difference between the two groups(P＜0.05).
3.The impact of Damp-heat on the course of PNS patients
The average duration of Damp-heat syndrome group is 42.13±46.49 months;and the average duration of non Damp-heat syndrome group is 29.18±29.27 months.The duration of PNS Damp-heat syndrome group are significantly longer than the non Damp-heat syndrome group.By statistical testing,there is difference between the two groups(P＜0.05).
4.The relationship between Damp-heat and infection
The percent of infection cases in the Damp-heat group(38.3%)is higher than the non Damp-heat group(16.7%).By statistical testing,there is significant difference between the two groups(P＜0.01).The Damp-heat group includes 11 cases(47.8%) of respiratory infections,5 cases (21.7%)of urinary tract infections,4 cases(17.4%) of gastrointestinal infection and other 3 cases(13.1%);The non Damp-heat group includes 5 cases(50.0%) of respiratory infections,3 cases(30%)of urinary tract infections,1 cases(10.0%) of gastrointestinal infection and other 1 cases(10.0%).By statistical testing,there is not difference between the two groups on the type of infection.
5.The impact of Damp-heat on the relapse of PNS patients
The percent of relapse in the Damp-heat group(65.0%) is higher than the non Damp-heat group(46.7%).By statistical testing,there is difference between the two groups(P＜0.05).
6.The impact of Damp-heat on the laboratory indicators of PNS patients
The total white blood cell of Damp-heat group(11.33±6.51*10e9/L) is significantly higher than the Damp-heat group' s(8.77±4.50*10e9/L).The Total cholesterol of Damp-heat group(10.99±4.00mmol/L) is higher than the Damp-heat group' s(8.19±2.53mmol/L). The 24-hour urinary protein of Damp-heat group(7.74±4.42 g/24h) is higher than the Damp-heat group' s(5.05±3.55 g/24h).By statistical testing,there is difference between the two groups on total white blood cell,Total cholesterol and 24-hour urinary protein(P＜0.05).But,by statistical testing,there is not difference between the two groups on Other laboratory indicator(P＞0.05).
7.The relationship between Damp-heat and Pathological types
In the collection of 120cases of PNS,there are 39 cases of patients having pathology report,accounted for 32.5 percent of total cases, including 20 cases of Damp-heat syndrome group and 19 cases of non Damp-heat syndrome group.The Damp-heat group includes 6 cases(30%) of Minimal change nephropathy,5 cases(25.0%) of Mesangial proliferative glomerulonephritis,8 cases(40.0%) of Membranous nephropathy and 1 case(5.0%)of Mesangial capillary glomerulonephritis.And the non Damp-heat group includes 4 cases(21.1%) of Minimal change nephropathy, 10 cases(52.6%) of Mesangial proliferative glomerulonephritis,3 case(15.8%) of Focal segmental glomerulosclerosis and 2 cases(10.5%) of Membranous nephropathy.The results showed that the membranous nephropathy patients of PNS Damp-heat Syndrome group are more than the non Damp-heat syndrome group' s.By statistical testing,there is difference between the two groups on membranous nephropathy(P＜0.05). But,by statistical testing,there is not difference between the two groups on other pathological types(P＞0.05).
8.The impact of Damp-heat on curative effect
The Damp-heat group includes 19 cases(31.7%) of complete remission, 12 cases(20.0%) of significant remission,10 cases(16.7%) of partial remission and 19 cases(31.7%) of invalid.The total effective rate of the Damp-heat group is 68.3 percent.The non Damp-heat group includes 24 cases(40.0%) of complete remission,17 cases(28.3%) of significant remission,9 cases(15.0%) of partial remission and 10 cases(16.7%) of invalid.The total effective rate of the non Damp-heat group is 83.3 percent.This shows the effective rate of Damp-heat syndrome group was lower than the non Damp-heat syndrome group.By statistical testing,there is difference between the two groups on effective rate(P＜0.05).
(二) Proteome research of Primary nephrotic syndrome Damp-heat syndrome
In proteomics research,That select 5 cases of normal control group, 10 cases of PNS Damp-heat syndrome group and 10 cases of non Damp-heat syndrome group to do serum Two-dimensional gel electrophoresis and mass spectrometry analysis.The experimental results show:The pictures are clear;There is no background interference stripes;The protein spots are completely separated;Under the same conditions and repeated 3 times,the experimental results similar to Figure;Through analysising the three sets of maps,there are finded out 1108 protein spots.Select the normal map as a reference gel,the other two groups with reference to glue rubber match,so that the gel of protein spots with reference to the corresponding glue together with the reference gel protein spots in the same match with the point of a protein.The results showed that the percentage of protein spots matched on the three sets of gel is about 80.12%.
The study use PDQuest software to analysis the differentially expressed protein in the two-dimensional gel images ofthe normal control group,PNS Damp-heat syndrome group and non Damp-heat group.Combined with the naked eye to distinguish,we found 19 protein spots in the gel three groups were significantly different in expression.By software analysis and manual selection,we selected six protein spots that are clear and obvious changes in expression levels from the differentially expressed protein to do mass spectrometry.The results of identified show that the No.2 protein is Apolipoprotein C-Ⅲ,the No.5 protein is Alpha-2-HS-glycoprotein,the No.8 protein is Immunoglobulin kappa 1-5, the No.10 protein is Inter-alpha-trypsin inhibitor heavy chain H2,the No.15 protein is Isoform 1 of Alpha-1-antitrypsin and the No.5 protein is Serotransferrin.Combined clinical and protein function,that the Apolipoprotein C-Ⅲandα2-HS-glycoprotein protein can be used as the specific expressed protein of PNS Damp-heat Syndrome.
Conclusion:
1.Form the data of the relationship between PNS Damp-heat and infection and recurrence,the study came to the conclusion that Damp-heat is an an important factor that Leads to recurrence of PNS patients.
2.Form the data of the relationship among PNS Damp-heat,course of disease,the days staying in hospital,blood lipids and urinary protein, efficacy,etc,;The study came to the conclusion that Damp-heat is an important factor that Leads to the condition of PNS patients exacerbate, procrastinate and Refractory.
3.Through analysising Serum protein silver staining 2-DE map of Normal control group,PNS Damp-heat syndrome group and non Damp-heat Syndrome, we found the differentially expressed proteins.
4.Through the identification of differences in protein,the study reached a preliminary view that Apolipoprotein C-Ⅲandα2-HS-glycoprotein protein can be used as evidence of the specific expressed protein of PNS Damp-heat.
方法:本课题主要采用横断面、前瞻、回顾性调查研究方法。通过调查收集符合纳入标准的原发性肾病综合征病例的一般情况、症状、体征、以及部分实验室检查指标,利用SPSS统计软件进行统计分析,全面系统分析湿热因素对原发性肾病综合征病程、病情、复发、实验室指标、疗效等影响。再采用最前沿的蛋白质组学方法,对原发性肾病综合征湿热证与非湿热证及健康对照组利用双向电泳进行差异蛋白分析,再利用质谱技术进行差异蛋白的鉴定。探讨原发性肾病综合征湿热证的分子机制,研究湿热证的本质。
结果:
(一)湿热因素对原发性肾病综合征临床病情的影响
本研究入选病例共120例,根据中医辨证分为湿热证组60例,非湿热证组60例。对两组病例的一般情况、症状、体征、实验室指标、疗效等进行分析比较,全面系统分析湿热因素对原发性肾病综合征病程、病情、复发、实验室指标、疗效等影响。结果如下:
1、一般资料分析湿热证组60例,其中男性47例,女性13例,年龄28.77±16.13岁;非湿热证组60例,其中男性为39例,女性为21例,年龄26.72±15.93岁;经统计学检验,两组在性别、年龄等方面无统计学差异(P＞0.05)。
2、湿热对原发性肾病综合征患者住院时间的影响湿热证组平均住院天数为23.90±11.75天,非湿热证组平均住院天数为16.00±7.47天,湿热证原发性肾病综合征患者住院时间明显长于非湿热证患者。经统计学检验,有统计学意义(P＜0.05)。
3、湿热对原发性肾病综合征患者病程的影响湿热证组平均病程为42.13±46.49月,非湿热证组平均为29.18±29.27月,湿热证原发性肾病综合征患者病程明显长于非湿热证患者。经统计学检验,有统计学意义(P＜0.05)。
4、湿热与伴发感染的关系湿热证组与非湿热证组感染情况比较,湿热证组伴发感染比例(38.3%)叫显高于非湿热证组(16.7%),经统计学检验后,有显著性差异(P＜0.01)。其中湿热证组伴有呼吸系感染者11(47.8%)例,泌尿系感染者5(21.7%)例,胃肠道感染4(17.4%)例,其他3(13.1%)例;非湿热证组伴有呼吸系感染者5(50.0%)例,泌尿系感染者3(30.0%)例,胃肠道感染1(10.0%)例,其他1(10.0%)例。两组在感染类别情况中并无差异,经统计学检验,无统计学意义(P＞0.05)。
5、湿热因素对肾病综合征病情复发的影响湿热证组与非湿热证组复发率比较,原发性肾病综合征湿热证组的复发率(65.0%)明显高于非湿热证组复发率(46.7%),经统计学检验后,有统计学意义(P＜0.05)
6、湿热对临床实验室指标的影响湿热证组与非湿热证组实验室指标比较中,湿热证组血白细胞总数(11.33±6.51*10e9/L)明显高于非湿热证血白细胞总数(8.77±4.50*10e9/L);湿热证组血清总胆固醇(10.99±4.00mmol/L)亦高于非湿热证组(8.19±2.53 mmol/L):湿热证组24小时尿蛋白定量(7.74±4.42 g/24h)大于非湿热证组(5.05±3.55 g/24h)。经统计学检验后,有统计学意义(P＜0.05)。而其他指标比较虽在数值上有一定的差异,但经统计学检验,并无统计学意义(P＞0.05)。
7、湿热与病理类型的关系在收集的120例肾病综合征病例中有39例有病理报告,占总病例的32.5%,其中湿热证组20例,非湿热证组19例。湿热证组病理类型中:微小病变肾病6例(30%);系膜增生性肾炎5例(25.0%);局灶性节段性肾小球硬化0例(0.0%);膜性肾病8例(40.0%);系膜毛细血管性肾小球肾炎1例(5.0%)。非湿热证组病理类型中:微小病变肾病4例(21.1%);系膜增生性肾炎10例(52.6%);局灶性节段性肾小球硬化3例(15.8%);膜性肾病2例10.5%);系膜毛细血管性肾小球肾炎0例(0.0%)。结果显示:原发性肾病综合征湿热证组病理类型中的膜性肾病明显多于非湿热证组,经统计学检验后,有统计学意义(P＜0.05),其它类型比较无明显差异,无统计学意义(P＞0.05)。
8、湿热对疗效的影响湿热证组完全缓解19例(31.7%),显著缓解12例(20.0%),部分缓解10例(16.7%),无效19例(31.7%),总有效率68.3%。非湿热证组完全缓解24例(40.0%),显著缓解17例(28.3%),部分缓解9例(15.0%),无效10例(16.7%),总有效率83.3%。可见湿热证组有效率明显低于非湿热证组。采用等级资料的秩和检验统计分析,有统计学意义(P＜0.05)。
(二)原发性肾病综合征湿热证的蛋白质组学研究
在蛋白质组学研究中,选取5例正常对照组、10例原发性肾病综合征湿热证组和10例非湿热证组进行血清双向凝胶电泳和质谱分析。实验结果:图像清晰,没有背景条纹的干扰,蛋白质斑点分离完全,在相同条件下,反复3次重复的实验结果图大致相同,三组图谱图象分析后平均检测到1108个蛋白质斑点。选取正常对照组图谱作为参考胶,其它两组胶与参考胶匹配,使各凝胶中的蛋白质斑点与参考胶中的对应起来,与参考胶中同一蛋白质斑点相匹配的点为同一种蛋白质。匹配结果显示三组胶蛋白质斑点匹配百分率约为80.12%。
用PDQuest软件将正常对照组、肾病综合征湿热证组和肾病综合征非湿热证组凝胶图像进行定性定量差异表达分析。结合肉眼分辨,我们发现有19个蛋白质斑点在三组凝胶中有显著差异表达。结合软件分析和手工筛选,我们从表达差异蛋白质点中选取6个点清晰且表达水平改变明显的蛋白质点作为最终质谱鉴定的对象。鉴定的结果为:2号蛋白为载脂蛋白C-Ⅲ(Apolipoprotein C-Ⅲ);5号蛋白为α_2-HS-糖蛋白(Alpha-2-HS-glycoprotein);8号蛋白为免疫球蛋白轻链k(Immunoglobulin kappa1-5);10号蛋白为间α-胰蛋白酶抑制因子重链的H2(Inter-alpha-trypsin inhibitor heavy chain H2);15号蛋白为α_1-抗胰蛋白酶(Isoform 1 of Alpha-1-antitrypsin);16号蛋白为血清转铁蛋白(Serotransferrin)。结合临床和蛋白质功能分析,其中载脂蛋白C-Ⅲ和α_2-HS-糖蛋白可作为原发性肾病综合征湿热证的特异表达蛋白,涉及功能主要与脂蛋白代谢、抗炎、抗胰岛素等有关。
结论:
1、由湿热与肾病综合征感染并发症、复发研究的资料分析提示:湿热是引起肾病综合征病情复发的重要因素。
2、由湿热与肾病综合征病程、住院时间、血脂、尿蛋白、疗效等资料分析提示:湿热是引起肾病综合征病情加重、迁延、难治的重要原因。
3、通过对健康对照组和原发性肾病综合征湿热证组及非湿热证组的血清蛋白银染2-DE图谱分析,我们发现确实存在差异表达蛋白。
4、通过对差异蛋白的鉴定分析,初步认为载脂蛋白C-Ⅲ和α_2-HS-糖蛋白可作为原发性肾病综合征湿热证的特异表达蛋白,涉及功能主要与脂蛋白代谢、抗炎、抗胰岛素等有关。
Objective:To guide clinical treatment of nephrotic syndrome,it was started with primary nephrotic Damp-heat and the first systematic research on the nephrotic syndrome of the impact of clinical conditions which is a comprehensive understanding of heat nephrotic syndrome on the impact of key links.With the purpous of further research in damp-heat syndrome with primary nephrotic syndrome and the possibility of the discovery of that specific protein,we analyzed the specific protein that could reveal the damp-heat syndrome of TCM nephrotic syndrome and the pathogenesis of the connotation.
Methods:To explore the molecular mechanism of Primary nephrotic syndrome Damp-heat,and the nature of Damp-heat.It was worked in the methods of cross-section,forward-looking and retrospective survey.To standard in line with the primary nephrotic syndrome,we investgated the patients in general,symptoms,signs,and some indicators of laboratory tests by using SPSS statistical software for statistical analysis to explore the Damp-heat factor in the onset primary nephrotic syndrome and the role in the course of its relevance.Systematically-analyzed the effects of the Damp-heat factors in each course of disease,condition, relapse,laboratory indicators,efficacy,etc.This study use the most cutting-edge proteomics approach,with primary nephrotic syndrome of damp-heat syndrome with non-heat Syndrome and healthy controls for differences in the use of two-dimensional gel electrophoresis protein analysis,and then carried out using mass spectrometry to identify protein differences.
Result:
(一) The impact of Damp-heat on the clinical condition of Primary nephrotic syndrome
In this study,a total of 120 cases of selected cases,including 60 cases of Damp-heat syndrome group and 60 cases of non Damp-heat syndrome group.Through analyzed and compared between the two groups in general, symptoms,signs,laboratory indicators,effects,this study systematically analysis the effects of the Damp-heat factor in the Drimary nephrotic syndrome patient's course of disease,condition,relapse, laboratory indicators,efficacy,etc.The results are as follows.
1.General data analysis
There are 60 cases of Damp-heat syndrome group,Including 47 males and 13 females,and their average age is 28.77±16.13 years old.There are 60 cases of non Damp-heat syndrome group,Including 39 males and 21 females,and their average age is 26.72±15.93 years old.By statistical testing,there is not significant difference between the two groups in gender,age and so on(P＞0.05).
2.The impact of Damp-heat on the days staying in hospital of PNS patients
The average days staying in hospital of Damp-heat syndrome group are 23.90±11.75 days;and the average days staying in hospital of non Damp-heat syndrome group are 16.00±7.47 days.The days staying in hospital of primary nephrotic syndrome Damp-heat syndrome group are significantly longer than the non Damp-heat syndrome group.By statistical testing,there is difference between the two groups(P＜0.05).
3.The impact of Damp-heat on the course of PNS patients
The average duration of Damp-heat syndrome group is 42.13±46.49 months;and the average duration of non Damp-heat syndrome group is 29.18±29.27 months.The duration of PNS Damp-heat syndrome group are significantly longer than the non Damp-heat syndrome group.By statistical testing,there is difference between the two groups(P＜0.05).
4.The relationship between Damp-heat and infection
The percent of infection cases in the Damp-heat group(38.3%)is higher than the non Damp-heat group(16.7%).By statistical testing,there is significant difference between the two groups(P＜0.01).The Damp-heat group includes 11 cases(47.8%) of respiratory infections,5 cases (21.7%)of urinary tract infections,4 cases(17.4%) of gastrointestinal infection and other 3 cases(13.1%);The non Damp-heat group includes 5 cases(50.0%) of respiratory infections,3 cases(30%)of urinary tract infections,1 cases(10.0%) of gastrointestinal infection and other 1 cases(10.0%).By statistical testing,there is not difference between the two groups on the type of infection.
5.The impact of Damp-heat on the relapse of PNS patients
The percent of relapse in the Damp-heat group(65.0%) is higher than the non Damp-heat group(46.7%).By statistical testing,there is difference between the two groups(P＜0.05).
6.The impact of Damp-heat on the laboratory indicators of PNS patients
The total white blood cell of Damp-heat group(11.33±6.51*10e9/L) is significantly higher than the Damp-heat group' s(8.77±4.50*10e9/L).The Total cholesterol of Damp-heat group(10.99±4.00mmol/L) is higher than the Damp-heat group' s(8.19±2.53mmol/L). The 24-hour urinary protein of Damp-heat group(7.74±4.42 g/24h) is higher than the Damp-heat group' s(5.05±3.55 g/24h).By statistical testing,there is difference between the two groups on total white blood cell,Total cholesterol and 24-hour urinary protein(P＜0.05).But,by statistical testing,there is not difference between the two groups on Other laboratory indicator(P＞0.05).
7.The relationship between Damp-heat and Pathological types
In the collection of 120cases of PNS,there are 39 cases of patients having pathology report,accounted for 32.5 percent of total cases, including 20 cases of Damp-heat syndrome group and 19 cases of non Damp-heat syndrome group.The Damp-heat group includes 6 cases(30%) of Minimal change nephropathy,5 cases(25.0%) of Mesangial proliferative glomerulonephritis,8 cases(40.0%) of Membranous nephropathy and 1 case(5.0%)of Mesangial capillary glomerulonephritis.And the non Damp-heat group includes 4 cases(21.1%) of Minimal change nephropathy, 10 cases(52.6%) of Mesangial proliferative glomerulonephritis,3 case(15.8%) of Focal segmental glomerulosclerosis and 2 cases(10.5%) of Membranous nephropathy.The results showed that the membranous nephropathy patients of PNS Damp-heat Syndrome group are more than the non Damp-heat syndrome group' s.By statistical testing,there is difference between the two groups on membranous nephropathy(P＜0.05). But,by statistical testing,there is not difference between the two groups on other pathological types(P＞0.05).
8.The impact of Damp-heat on curative effect
The Damp-heat group includes 19 cases(31.7%) of complete remission, 12 cases(20.0%) of significant remission,10 cases(16.7%) of partial remission and 19 cases(31.7%) of invalid.The total effective rate of the Damp-heat group is 68.3 percent.The non Damp-heat group includes 24 cases(40.0%) of complete remission,17 cases(28.3%) of significant remission,9 cases(15.0%) of partial remission and 10 cases(16.7%) of invalid.The total effective rate of the non Damp-heat group is 83.3 percent.This shows the effective rate of Damp-heat syndrome group was lower than the non Damp-heat syndrome group.By statistical testing,there is difference between the two groups on effective rate(P＜0.05).
(二) Proteome research of Primary nephrotic syndrome Damp-heat syndrome
In proteomics research,That select 5 cases of normal control group, 10 cases of PNS Damp-heat syndrome group and 10 cases of non Damp-heat syndrome group to do serum Two-dimensional gel electrophoresis and mass spectrometry analysis.The experimental results show:The pictures are clear;There is no background interference stripes;The protein spots are completely separated;Under the same conditions and repeated 3 times,the experimental results similar to Figure;Through analysising the three sets of maps,there are finded out 1108 protein spots.Select the normal map as a reference gel,the other two groups with reference to glue rubber match,so that the gel of protein spots with reference to the corresponding glue together with the reference gel protein spots in the same match with the point of a protein.The results showed that the percentage of protein spots matched on the three sets of gel is about 80.12%.
The study use PDQuest software to analysis the differentially expressed protein in the two-dimensional gel images ofthe normal control group,PNS Damp-heat syndrome group and non Damp-heat group.Combined with the naked eye to distinguish,we found 19 protein spots in the gel three groups were significantly different in expression.By software analysis and manual selection,we selected six protein spots that are clear and obvious changes in expression levels from the differentially expressed protein to do mass spectrometry.The results of identified show that the No.2 protein is Apolipoprotein C-Ⅲ,the No.5 protein is Alpha-2-HS-glycoprotein,the No.8 protein is Immunoglobulin kappa 1-5, the No.10 protein is Inter-alpha-trypsin inhibitor heavy chain H2,the No.15 protein is Isoform 1 of Alpha-1-antitrypsin and the No.5 protein is Serotransferrin.Combined clinical and protein function,that the Apolipoprotein C-Ⅲandα2-HS-glycoprotein protein can be used as the specific expressed protein of PNS Damp-heat Syndrome.
Conclusion:
1.Form the data of the relationship between PNS Damp-heat and infection and recurrence,the study came to the conclusion that Damp-heat is an an important factor that Leads to recurrence of PNS patients.
2.Form the data of the relationship among PNS Damp-heat,course of disease,the days staying in hospital,blood lipids and urinary protein, efficacy,etc,;The study came to the conclusion that Damp-heat is an important factor that Leads to the condition of PNS patients exacerbate, procrastinate and Refractory.
3.Through analysising Serum protein silver staining 2-DE map of Normal control group,PNS Damp-heat syndrome group and non Damp-heat Syndrome, we found the differentially expressed proteins.
4.Through the identification of differences in protein,the study reached a preliminary view that Apolipoprotein C-Ⅲandα2-HS-glycoprotein protein can be used as evidence of the specific expressed protein of PNS Damp-heat.
引文
[1]刘宏伟.肾病湿热证的实验研究进展[J].中国中医基础医学杂志,1995;1(4):35.
[2]余江毅,熊宁宁,余承惠等.肾病湿热病理的临床分析和实验研究[J].中国中西医结合杂志,1992;12(8):458-460.
[3]时振声.时氏中医肾脏病学[M].北京:中国医药科技出版社,1997,1.
[4]傅文录,王天明,田献忠等.肾脏病(专科专病名医临证经验丛书)[M].北京:人民卫生出版社,2002,180.
[5]焦安钦,徐进秀.原发性肾小球肾炎与湿热虚瘀[J].山东中医学院学报,1995;19(2):105.
[6]张大宁.中医补肾活血法研究[M].北京:中国医药科技出版社,1997,156-164.
[7]杨广锐.自拟肾病复康煎剂治疗38例肾病综合征临床观察[J].北京中医,1998;(1):27-28.
[98]高菁.辨证论治为主治疗肾病综合征100例[J].北京中医药大学学报,1996;19(3):32-34.
[9]李荣藻.试论益气养阴法在成人肾病综合征治疗中的应用[J].实用中西医结合杂志,1995;8(5):275.
[10]左澄章.难治性肾病59例疗效分析[J].吉林中医药,1998;(5):26.
[11]王兆颜.中西医结合治疗肾病综合征33例[J].山东中医杂志,1996;15(9):410.
[12]孙中理.活血益肾汤治疗肾病型肾炎22例[J].四川中医,1997;15(10):32.
[13]闫树河.中医药治疗肾病综合征30例临床观察[J].中国中医药信息杂志,1999;6(7):56.
[14]陈一清.肾病综合征证治规律探讨[J].山东中医杂志,1999;18(1):3
[15]冯天保.谢桂权教授治疗难治性肾病综合征经验撷菁[J].中医药学刊,2005;23(9):1574.
[16]宁为民,詹利霞,何世东.治疗顽固性原发性肾病综合征经验[J].疑难病杂志,2003;2(5):309-310.
[17]王少华,赵德喜,孙元荣.张琪治疗原发性肾病综合征的经验[J].山西中医,2000;16(5):5.
[18]吕贵东.王瑞道主任医师治疗肾病综合征的经验[J].陕西中医,1997;18(4):170.
[19]沈庆法,张瑾.难治性'肾病综合征的中医辨证治疗[J].中国医刊,1999;34(10):7.
[20]李文浩.中西医结合治疗原发性肾病综合征72例[J].中国中医药信息杂志,1999:6(1):50.
[21]王少华,赵德喜,孙元荣.张琪治疗原发性肾病综合征的经验[J].山西中医,2000;16(5):5.
[22]张丽洁.浅谈肾病综合征的治疗经验[J].中华中西医学杂志,2008;6(8):25.
[23]杨玉莲,陈小永.中西医结合治疗难治性肾病综合征临床观察[J].四川中医,2007;25(4):62-63.
[24]袁永华.分阶段多联疗法治疗难治性肾病综合征40例[J].安徽中医临床杂志,2002;14(5):353-354.
[25]牛学任.中西医结合治疗肾病综合征23例[J].河南中医,2006;26(1):66.
[26]李典高,左菊英,彭方.中西医结合治疗原发性肾病综合征临床观察[J].中国中西医结合杂志,1999;19(9):552.
[27]建宁,王宁丽.中西医结合治疗原发性肾病综合征180例观察[J].中国中西医结合肾病杂志,2001:2(8):468.
[28]杨绍华.中西医结合治疗小儿难治性综合征30例[J].四川中医,1998;16(3):34.
[29]周硕果.浅谈肾病综合征的中医辨证[J].中医药临床杂志,2005;17(6):562-563.
[30]许健.中医分型治疗复发性。肾病综合征18例[J].辽宁中医杂志,2004;31(8):659.
[31]韦先进.朱辟疆教授中西医结合治疗原发性肾病综合征经验[J].中国中西医结合肾病杂志,2003;4(5):301.
[32]高菁,吕仁和,刘玉芹等.辨证论治为主治疗。肾病综合征100例[J].北京中医药大学学报,1996;19(3):32.
[33]王玲,刘美茹,孙建新.从肺脾肾论治肾病综合征[J].甘肃中医,1997;10(1):6.
[34]陆安康.调理脾肾在肾病综合征中的应用[J].黑龙江中医药,1997;20(5):28.
[35]韩履棋,王琴.难治性肾病综合征从肝论治[J].浙江中医杂志,2000;35(2):75.
[36]刘新祥,毛以林,周珂等.脾肾双补法为主综合治疗原发性肾病综合征临床疗效观察[J].中国中西医结合肾病杂志,2001;2(3):149.
[37]毛以林,刘新祥,朱莹.脾肾双补法治疗原发性肾病综合征48例疗效观察[J].湖南中医杂志,2001;17(6):15.
[38]李萌昆.益肾健脾治疗原发性肾病综合征临床观察[J].中国中医药信息杂志2000;7(6):62.
[39]庄德治,庄德成.健脾益肾法治疗肾病综合征33例疗效观察[J].镇江医学院学报,1999;19(1):139.
[40]沈庆法.肾脏病湿热证的研究[J].浙江中医学院学报,2002;24(1):39.
[41]王琦.中医体质学[M].北京:中国医药科技出版社,1995:296-299.
[42]张红敏,王丽英,丁樱.肾小球系膜病理损害的中医病机初探[J].陕西中医,2004; 25(12):1121.
[43]肖敬.史伟教授从湿热蜜治难治性肾病综合征的经验[J].四川中医,2007;25(11):3-4.
[44]叶景华.慢性肾炎中医药研究现状及展望[J].山东中医杂志,1994;13(1):11.
[45]沈庆法.肾病湿热证的研究(续)[J].浙江中医学院学报,2000;24(2):18.
[46]熊宁宁,余江毅,余承惠等.慢性肾炎湿热证病理机制的研究[J].辽宁中医杂志,1995;22(8):343.
[47]张福生,杨颖.慢性肾炎湿热证客观指标的变化[J].浙江中医杂,1995;(7):322.
[48]张福生,杨保永,张连明等.慢性肾炎湿热证肾小管功能研究[J].辽宁中医杂志,1996:23(12):533.
[49]余江毅,熊宁宁,余承惠等.慢性肾病瘀血与湿热病理的临床和实验研究[J].中医杂志,1995;22(2):91.
[50]邓银泉.慢性肾炎辨证论治与血浆纤维结合蛋白的关系[J].辽宁中医杂志,1998;25(3):103.
[51]吴仕九,廖礼兵.湿热证大鼠肾内髓及尿液中水通道蛋白AQP2含量的变化[J].中国中医药科技,2003;10(1):4.
[52]朱绍琼,金红,谭泽民等.小儿肾性水肿中医辨证分型与血清学指标的关系初探[J].中华实用中西医杂志,2004;4(17):351.
[53]张光荣,徐友妹,皮持衡等.肾病综合征辨证分型与血总纤容活力、超氧化物歧化酶及血清白蛋白的关系[J].中国中西医结合杂志,1994;14(5):274.
[54]刘慰祖,陈以平,徐篙年等.肾小球肾炎患者补体旁路途径活性的测定及中药治疗前后的变化[J].中西医结合杂志,1986;6(4):210.
[55]熊宁宁,徐长照.家兔肾炎湿热模型的实验研究[J].辽宁中医杂志,1991;(4):42.
[56]刘宏伟.原发性肾小球疾病肾小球内补体成分测定与中医辨证分型的关系[J].辽宁中医杂志,1993;(3):1.
[57]李俊彪,莫穗林,朱雅宜.丹芍汤提高阴虚湿热型慢性肾炎患者红细胞免疫功能的临床研究[J].南京中医药大学学报,1996;12(2):18.
[58]盛梅笑,孙伟,贾宁人等.肾炎湿热证血清sICAM-1变化的临床观察[J].辽宁中医杂志,2003;30(11):891.
[59]张红梅,陈雪功,王望九等.慢肾蛋白停防治实验性慢性肾炎湿热证及对白细胞Fc 受体的影响[J].中国中西医结合急救杂,2004;11(1):34.
[60]朱辟疆,刘永平,田军民等.慢性肾小球疾病湿热证T淋巴细胞亚群及IL-2,sIL-2R的改变[J].中国中医药科技,1999;6(3):148.
[61]朱辟疆,施荣华,刘记平.慢性肾小球疾病湿热证血浆及尿白介素-6的改变[J].浙江中西医结合杂志,1999;9(2):75.
[62]朱辟疆,韦先进,江丽萍等.慢性肾小球疾病尿细胞因子改变及其与中医证型的关系[J].现代中西医结合杂志,2005;14(1):20.
[63]余江毅,熊宁宁,余承惠等.慢性肾病瘀血与湿热病理的临床和实验研究[J].中医杂志,1995:22(2):91.
[64]王付民.慢性肾小球肾炎病理类型与中医分型相关性研究[J].辽宁中医杂志,1994;21(9):392.
[65]陆军,周易谦,崔爱东.成人原发性肾病综合征的中医辨证与病理类型的关系[J].实用中西医结合杂志,1998;11(10):863.
[66]阮诗玮,郑敏麟,王智等.IgA肾病湿热证与肾穿刺活检病理组织关系的临床研究[J].中国中西医结合肾病杂志,2003;4(10):583.
[67]孙伟,曾安平,严志林等.湿热病邪与慢性肾病关系探讨[J],中医研究,2000;13(1):37.
[68]侯安会,王磊.肾病湿热探讨[J].黑龙江中医,2000;(1):5.
[68]傅文录.时振声辨治肾病湿热证经验[J].中医研究,1995;8(3):24.
[70]卢远航.以湿热论治肾病综合征191例[J].陕西中医,1998;19(10):439-440.
[71]第二届全国中医肾病学术会议[J].陕西中医,1988;(1):4.
[72]方小南.龙胆泻肝汤加减治疗难治性'肾病综合征18例疗效观察[J].中国中医基础医学杂志,2002;8(8):60.
[73]周玉来.中西医结合治疗湿热型难治性肾病综合16例[J].中医研究,2002;15(3):37.
[74]谢惠芬,植金川,魏彦国.中西医结合治疗原发性肾病综合征105例[J].陕西中医,1994;15(4):152.
[75]林鹤和,曹康永,董建华等.肾病综合征[M].北京:中国中医药出版社,1992:77.
[76]刘建国.中西医结合治疗难治性肾病的良方妙法[M].北京:中国医药科技出版社,2000:138.
[77]程星.辨证分型治疗肾病等50例[J].福建中医药,1987;(1):18.
[78]朱辟疆.滋阴活血解毒利湿中药治疗难治性肾病综合征70例观察[J].中西医结合杂志,1989:(2):104.
[79]王钢.肾炎合剂Ⅱ号治疗原发性肾病综合征77例临床疗效总结[J].江苏中医,1993;14(4):10.
[80]何小萍.中西医结合治疗原发性肾病综合征48例[J].河南中医药学刊,1998;13(5):35.
[81]谢桂权,高颍,冯天保等.清热利湿法治疗肾病综合征湿热证45例疗效观察[J].新中医,2007;39(10):58-87.
[82]Wasinger VC,Cordwell SJ,Cerpa-Poljak A.et al.Progeress withgenne-product mapping of the Mollicutes:Mycoplasma genitalium[J].Electrophoresis,1995,16(7):1090-1094.
[83]R.Constellations in a cellular universe[J].Nature,2003,422:115
[84]金光亮.证候基因组学和证候蛋白质组学浅论[J].中国医药报,2003;16(8):332-335
[85]Farrell PH,High resolution two-dimensional eletrophoresis ofproteins.Biol Chem,1975:250:4007.
[85]Klose J,Kobalz U.Two dimensional eletrophoresis of proteins anupdated proteocol and implications for a function analysia of thegenome.Electrophoresis,1995:16:1034.
[87]Molloy MP.T wo-dimensional eletrophoresis of membrane proteins using immobilized pH gradients.Anal Biochem,2000;280:1.
[88]Fey SI,Larsen PM.2D or not 2D.Two dimensional eletrophoresis.CurrOpin Chem Biol,2001;5:26.
[89]Klein E,Klein JB,Thongboonkerd V.Two-dimensional eletrophoresis a fundamental tool for expression proteomics studies.Contrib Nephrol,2004:141:25.
[90]Gioraianni F,Deside rio DM,Beranova-Gioorgianni S Proteome analysis using isoelectric focusing in immobilized pHguadient gels followed by mass apectrometry.Electrophoresis,2003;24:253.
[91]GorgA,Wejss W,DunnMJ Current two-dimensional electrophoresis technology for proteomics.Protemics,2004:4(12):3665.
[92]GorgA,BoguthG,KopfA.Sample prefractionation with Sephadex Isoelectric focusingpriortonarrow pH range two dimensional gels.Proteomics,2002;2(12):1652-1657.
[93]GorgA,ObermaierC,BoguthG.The current state of two-dimension Electrophoresiswith immobilized pH gradients.Electrophoresis,2000:21(6):1037-1053.
[94]RabilloudT.Silver staining of 2D electrophoresisgels.Methods MolBio,1999:112:297-305.
[95]MatsuiNM.Staining of preparative 2Dgels:Coomassie blue andimidazole-zincnegative staining.Methds MolBio,1999:112:307-311.
[96]LinkAJ.Auto radiographyof 2D gels.Methods MolBio,1999:112:285-290.
[97]WaterborgJH,MatthewsHR.Fluorography of polyacryla midege lscontainig tritium.Methods Mol Bio,1994:32:163-167.
[98]Lopez MF,Berggren K,ChernokalskayaE.A comparison of silver stainAnd SYPROR ubyProtein Gel Stain with respect toproteindetection intwo —dimension algels and identification by peptide mass profiling.Electrophoresis,2000;21(17):3673-3683.
[99]LopezMF,KristalBS,ChernokalskayaE.High-through put profiling of The mitochondrial proteome using affinity fractionation and automation.Electrophoresis,2000;21(16):3427-3440.
[100]Brown RS,Lennon JJ.Mass resolution improvement by incorporation of pulsed ion extraction in a matrix-assisted laser desorption/ionization linear time-of-flight mass spectrometer [J].Anal Chem,1995,67(13):1998-2003.
[101]Wilkes JG,Zarrin F,Lay JO JR,Vestal ML.Particle size distribution is not the major factor explaining variable analyze transmission efficiency in liquid chromatography/particle beam/mass spectrometry [JJ.Rapid Commun Mass 1995,9(2):133-137.
[102]Podtelejnikov A,Mann M.Delayed extraction improves specificity in database searches by matrix-assisted laser desorption/ionization peptide maps[J].Rapid Commun Mass Spectrom,1996,10(11):1371-1378.
[103]Vogeser M.Liquid chromatography-tandem mass spectrometry application in the clinical laboratory [J].Clin Chem Lab Med,2003,41(2):117-126.
[104]Smyth WF,Brooks PA.Critical evaluation of high performance liquid chromatography-electrospray ionisat ion-mass spectrometry and capillary electrophoresis-electrospray-mass pectrometry for the detection and determination of small molecules of significance in clinical and forensic science [J].Electrophoresis,2004,25(10-11):1413-1446.
[105]Verentchikov AN,Ens W,Standing KG.Reflecting time-of-flight mass pectrometer with an electrospray ion source and orthogonal extraction [J].Anal Chem,1994,66(1):126-133.
[106]Li J,Wang C,Kelly JF,Harrison DJ,Thibault P.Rapid and sensitive separation of trace level protein digests using microfabricated devices coupled to a quadrupole—time-of-flight mass spectrometer [J].Electrophoresis,2000,21 (1):198-210.
[107]Kristensen DB,Imamura K,Miyamoto Y,Yoshizato K.Mass spectrometric approaches the characterization of proteins on a hybrid quadrupole time-of-flight (Q-T0F)mass spectrometer [J].Electrophoresis,2000, 21(2):430-439.
[108]Colsch B,Afonso C,Popa I,Portoukalian J,Fournier F,Tabet JC,Baumann N.Characterization of the ceramide moieties of sphingog]ycolipids from mouse brain by ESI-MS/MS:identification of ceramides containing sphingadienine[J].J Lipid Res,2004,45(2):281-286.
[109]GovorunVM,etal.Proteomic technologies in modern biomedical science.Biochemistry(Moscow),2002:67(10):1109.
[110]叶雪清,曾淑华,张宛明等.月经失调的八纲辨证与植物神经系统功能关系的研究[J].中西医结合杂志,1984,4(4):198.
[111]叶雪清,杨少文,李安,等.阳虚患者植物神经系统功能、甲微循环和血液流变学的改变及相互作用[J].中西医结合杂志,1989,9(10):618.
[112]陆启滨,夏桂成,陈丹华等.159例绝经前后诸证阴虚火旺型患者的植物神经功能观察[J].上海中医药杂志.1990,(2):12.
[113]全建峰,吴晓康,孙晓虹.肾阴虚证患者的血清免疫球蛋白G、A、M及补体C_3、C_4相关性研究[J].现代中医药,2004,5(2):53-54.
[114]蔡宛如,汤军,徐志瑛等.肺心病痰热型与痰热伤阴型的免疫学指标观察[J].中国医药学报,2000,15(2):43.
[115]秦路平,张家庆.蛇床子香豆素对肾阳虚模型大鼠腺垂体-肾上腺皮质轴功能的影响[J].中国中西医结合杂志,1997,17(4):227-229.
[116]樊蔚虹,岳广欣,任小巧,等.肝肾阴虚证大鼠下丘脑垂体-甲状腺轴的变化及中药对其调节作用[J].中国中医药信息杂志,2001,8(10):21.
[117]丘瑞香,吴国珍,金明华.性激素对肾虚患者阴阳平衡的调节作用[J].中国中医基础医学杂志,1999,5(3):46.
[118]薛沙,汤学军.右归丸对肾阳虚动物模型血液微量元素含量的影响[J].中国中医药科技,2002,7(3):168-169.
[119]申维玺,孙燕,刘晓燕,等.用现代医学理论阐明肾阴虚证的本质和发病学机制[J].医学与哲学,2005,26(11):67-69.
[120]陈小野.证候实质研究中弱特异性的正面观[J].医学与哲学,1995,16(6):311-313.
[121]刘为民.中医证候学研究与证候蛋白质组学[J].中医药学报,2003;(31):3-7.
[122]余宗阳,杜建.蛋白质组学与中医证候实质研究[J].中国中西医结合杂志,2004;24(9):844-846.
[123]申维玺.论中医“证本质“的科学内涵[J].中国中医基础医学杂志,2001;7(6):410.
[124]申维玺,孙燕.论中医药的化学本质是蛋白质和肽及证本质的分子标准[J].中国 中西医结合杂志,1999;19(11):696.
[125]申维玺,孙燕.用分子生物学理论阐释阴虚证的本质[J].医学研究通讯,1998;27(8):1.
[126]刘为民.中医证候学研究与证候蛋白质组学[J].中医药学报,2003;31(3):1.
[127]邱德有,吴小红,黄璐琦.现代生命科学技术对中医药发展的影响[J].世界科学技术,2001;3(2):12.
[128]TONGE R,SHAW J,MIDDLETON B,et al.Validation and development of Fluorescence two-dimensional differential gelelectrophoresis proteomics technology[J].Proteomies,2001;1(3):377-396.
[129]马增春,高月.复方丹参片对冠心病患者血浆蛋白影响的蛋白质组学研究[J].中国中药杂志,2006;31(9):766-769.
[130]钟小兰,吕志平,钱令嘉等.束缚所致肝郁证动物模型肝组织蛋白质组的差异表达研究[J].中医杂志,2006;47(5):371-373.
[131]刘丽丽,马增春,王宇光等.四物汤对环磷酰胺致血虚证小鼠骨髓蛋白质组的影响[J].中国中药杂志,2006;31(14):1172-1175.
[132]卢德赵,沃兴德,施孟如等.激素型肾阳虚动物肝线粒体蛋白质组与能量代谢相关性[J].中国生物化学和分子生物学报,2005:21(6):807-814.
[133]王海彬,刘建仁,樊粤光等.中药治疗大鼠去卵巢骨质疏松症的蛋白质组学分析[J].四川中医.2006;24(8):9-13.
[134]张莺,陈泽奇,钟广伟.平肝潜阳法对高血压模型大鼠下丘脑蛋白质表达的影响[J].广州中医药大学学报,2008;25(4):325-331.
[135]杨波,梁清华,蔡颖等.痹肿消汤干预胶原诱导性关节炎大鼠滑膜病变的蛋白质组学研究[J].中国临床康复,2006;10(15):74-78.
[136]郭平,马增春,李鹰飞等.四物汤对放射线致血虚证小鼠骨髓蛋白质表达的影响[J].中国中药杂志,2004;29(9):893-896.
[137]吴伟康,李劲平.四逆汤抗心肌缺血作用的相关蛋白谱研究[J].中国病理生理杂志,2005:21(3):506-510.
[138]姜楠,霍海如,李兰芳等.桂皮醛对发热大鼠下丘脑蛋白质组双向凝胶电泳分析[J].中药药理与临床,2003:19(6):11-13.
[139]张萃,王培训,周联等.活血化瘀中药对内毒素诱导THP21细胞增殖及蛋白质组的影响[J].中国免疫学杂志,2006:22(7):665-670.
[140]宋元英,王忠,曲迅等.中药不同组分对小鼠缺血脑组织蛋白表达谱的影响[J].中国中西医结合杂志,2006;26(6):526-528.
[141]张萃,王培训,周联等.活血化瘀中药对内毒素诱导THP-1细胞增殖及蛋白质组的影响[J].中国免疫学杂志,2006;22:662-670.
[142]上海第二医科大学附属仁济医院中医内科肾病组.成人肾病综合征267例的治疗体会[J].新医药学杂志,1978;(3):22.
[143]孙伟,曾安平,严志林等.湿热病邪与慢性肾病关系探讨[J].中医研究,2000;13(1):37.
[144]朱学云,钱卫东.高脂血症中医药研究进展[J].江苏中医,1998;19(6):46-471.
[145]谢桂权.中医药治疗慢性肾炎蛋白尿七法[J].新中医,1986;19(2):28-30.
[146]Sophia N,Lavrendadou,Margarita Hadzopoulou-Cladaras,Dmitris Kardassis and Vassihs I.Zannis[J].Biochemistry,1999;38:964-975.
[147]Weisgraher,Fmchart J C,Dufiez P.Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism[J].Drugs Today,2006;42(1):39-64.
[148]Woltje M,Tschoke B,von Bulow V,et al.CCAAT enhancer bindinprotein beta and hepatocyte nuclear factor 3beta are necessary ansufficient to mediate dexamethasone-induced up-regulation of alpha2 HS-glycoprotein/fetuin-A gene expression[J].J MEndocrinol,2006;36(2):261-277.
[149]Mathews ST,Chellam N,Srinivas PR,et al.Alpha(2)-HSG,a specifinhibitor of insulin receptor autophosphorylation,interacts with thinsulin receptor[J].Mol Cell Endocrinol,2000;164(1-2):87-98.
[150]Stefan N,Hennige AM,Staiger H,et al.Alpha2-Heremans-Schmid glycoprotein/fetuin-A is associated with insulin resistan ce and faaccumulation in the liver in humans[J].Diabetes Care,2006;29(4853.857.
[151]Mathews ST,Singh GP,Ranalletta M,et al.Improved insulsensitivity an d resistance to weight gain in mice null for the Ahsgone[J]1.Diabetes,2002;51(8):2450-2458.
[152]l Mathews ST,Rakhade S,Zhou X,et al.Fetuin.null mice arprotected against obesity and insulin resistance associated with agin[J].Biochem Biophys Res Commun,2006;350(2):437-443.
[153]Price PA,Thomas GR,Pardini AW,et al.Discovery of a higmolecular wei ght complex of calcium,phosphate,fetuin and matrigamma -carboxyglutamic acid protein in the serum of etidronatetreated rats[J].J Biol Chem,2002;277(6):3926-3934.
[154]Heiss A,DuChesne A,Denecke B,et al.Structural basis calcification inhibition by alpha 2-HS glycoprotein/fetuin-A Formation of colloidal.calciprotein particles[J].J Biol Chem,2003;278(15):13333-13341.
[155]Szweras M,Liu D,Partridge EA,et al.2-HS glycoprotein/fetuin,atransforming growth factor-lB/bone morphogenetic protein antagonist,regulates postnatal bone growth and remodeling[J].J Biol Chem,2002:277(22):19991-19997.
[156]Gangneux C,Daveau M,Hiron M,et al.The inflammation-induced down-regulation of plasma Fetuin-A(2HS-Glycoprotein) in liverresults from the loss of interaction between long C/EBP isoforms attwo neighbouring binding sites[J].Nucleic Acids Res,2003:31(20):5957-5970.
[157]Georgina Reh,Bibiana Nerli,Guillermo Pico.Isolation of alpha-l-antitrypsin from human plasma by partitioning in aqueous biphasic systems of polyethyleneglycol-phosphate[J].Joumal of Chromatography B,2002:780:389-396.
[158]Hyun Kyu Song.Crystal structure of uncleavedet I-antitrypsin reveals the conformation of its inhibitory reactive loop[J].FEBS Letters,1995;377:150-154.
[159]hezdey J,et al.Treatment of osteocarcinama with alpha-l-anti-trypsin or secretory leucocyte proteinaso inhibitor[M]USP6670325,Dec 30,2003;30(10):56-59
[160]董淑兰,刘伟龟,张秋业等.肾病综合征病儿血清α_1-抗胰蛋白酶的变化及临床意义[J].青岛医学院学报,1992;28(3):28-29.
[161]Brown WM.rAAt(inhaled) Arriva/Hyland[J].lmmuno.Curr Opin Mol Ther,2006:8(1):76-82.
[2]余江毅,熊宁宁,余承惠等.肾病湿热病理的临床分析和实验研究[J].中国中西医结合杂志,1992;12(8):458-460.
[3]时振声.时氏中医肾脏病学[M].北京:中国医药科技出版社,1997,1.
[4]傅文录,王天明,田献忠等.肾脏病(专科专病名医临证经验丛书)[M].北京:人民卫生出版社,2002,180.
[5]焦安钦,徐进秀.原发性肾小球肾炎与湿热虚瘀[J].山东中医学院学报,1995;19(2):105.
[6]张大宁.中医补肾活血法研究[M].北京:中国医药科技出版社,1997,156-164.
[7]杨广锐.自拟肾病复康煎剂治疗38例肾病综合征临床观察[J].北京中医,1998;(1):27-28.
[98]高菁.辨证论治为主治疗肾病综合征100例[J].北京中医药大学学报,1996;19(3):32-34.
[9]李荣藻.试论益气养阴法在成人肾病综合征治疗中的应用[J].实用中西医结合杂志,1995;8(5):275.
[10]左澄章.难治性肾病59例疗效分析[J].吉林中医药,1998;(5):26.
[11]王兆颜.中西医结合治疗肾病综合征33例[J].山东中医杂志,1996;15(9):410.
[12]孙中理.活血益肾汤治疗肾病型肾炎22例[J].四川中医,1997;15(10):32.
[13]闫树河.中医药治疗肾病综合征30例临床观察[J].中国中医药信息杂志,1999;6(7):56.
[14]陈一清.肾病综合征证治规律探讨[J].山东中医杂志,1999;18(1):3
[15]冯天保.谢桂权教授治疗难治性肾病综合征经验撷菁[J].中医药学刊,2005;23(9):1574.
[16]宁为民,詹利霞,何世东.治疗顽固性原发性肾病综合征经验[J].疑难病杂志,2003;2(5):309-310.
[17]王少华,赵德喜,孙元荣.张琪治疗原发性肾病综合征的经验[J].山西中医,2000;16(5):5.
[18]吕贵东.王瑞道主任医师治疗肾病综合征的经验[J].陕西中医,1997;18(4):170.
[19]沈庆法,张瑾.难治性'肾病综合征的中医辨证治疗[J].中国医刊,1999;34(10):7.
[20]李文浩.中西医结合治疗原发性肾病综合征72例[J].中国中医药信息杂志,1999:6(1):50.
[21]王少华,赵德喜,孙元荣.张琪治疗原发性肾病综合征的经验[J].山西中医,2000;16(5):5.
[22]张丽洁.浅谈肾病综合征的治疗经验[J].中华中西医学杂志,2008;6(8):25.
[23]杨玉莲,陈小永.中西医结合治疗难治性肾病综合征临床观察[J].四川中医,2007;25(4):62-63.
[24]袁永华.分阶段多联疗法治疗难治性肾病综合征40例[J].安徽中医临床杂志,2002;14(5):353-354.
[25]牛学任.中西医结合治疗肾病综合征23例[J].河南中医,2006;26(1):66.
[26]李典高,左菊英,彭方.中西医结合治疗原发性肾病综合征临床观察[J].中国中西医结合杂志,1999;19(9):552.
[27]建宁,王宁丽.中西医结合治疗原发性肾病综合征180例观察[J].中国中西医结合肾病杂志,2001:2(8):468.
[28]杨绍华.中西医结合治疗小儿难治性综合征30例[J].四川中医,1998;16(3):34.
[29]周硕果.浅谈肾病综合征的中医辨证[J].中医药临床杂志,2005;17(6):562-563.
[30]许健.中医分型治疗复发性。肾病综合征18例[J].辽宁中医杂志,2004;31(8):659.
[31]韦先进.朱辟疆教授中西医结合治疗原发性肾病综合征经验[J].中国中西医结合肾病杂志,2003;4(5):301.
[32]高菁,吕仁和,刘玉芹等.辨证论治为主治疗。肾病综合征100例[J].北京中医药大学学报,1996;19(3):32.
[33]王玲,刘美茹,孙建新.从肺脾肾论治肾病综合征[J].甘肃中医,1997;10(1):6.
[34]陆安康.调理脾肾在肾病综合征中的应用[J].黑龙江中医药,1997;20(5):28.
[35]韩履棋,王琴.难治性肾病综合征从肝论治[J].浙江中医杂志,2000;35(2):75.
[36]刘新祥,毛以林,周珂等.脾肾双补法为主综合治疗原发性肾病综合征临床疗效观察[J].中国中西医结合肾病杂志,2001;2(3):149.
[37]毛以林,刘新祥,朱莹.脾肾双补法治疗原发性肾病综合征48例疗效观察[J].湖南中医杂志,2001;17(6):15.
[38]李萌昆.益肾健脾治疗原发性肾病综合征临床观察[J].中国中医药信息杂志2000;7(6):62.
[39]庄德治,庄德成.健脾益肾法治疗肾病综合征33例疗效观察[J].镇江医学院学报,1999;19(1):139.
[40]沈庆法.肾脏病湿热证的研究[J].浙江中医学院学报,2002;24(1):39.
[41]王琦.中医体质学[M].北京:中国医药科技出版社,1995:296-299.
[42]张红敏,王丽英,丁樱.肾小球系膜病理损害的中医病机初探[J].陕西中医,2004; 25(12):1121.
[43]肖敬.史伟教授从湿热蜜治难治性肾病综合征的经验[J].四川中医,2007;25(11):3-4.
[44]叶景华.慢性肾炎中医药研究现状及展望[J].山东中医杂志,1994;13(1):11.
[45]沈庆法.肾病湿热证的研究(续)[J].浙江中医学院学报,2000;24(2):18.
[46]熊宁宁,余江毅,余承惠等.慢性肾炎湿热证病理机制的研究[J].辽宁中医杂志,1995;22(8):343.
[47]张福生,杨颖.慢性肾炎湿热证客观指标的变化[J].浙江中医杂,1995;(7):322.
[48]张福生,杨保永,张连明等.慢性肾炎湿热证肾小管功能研究[J].辽宁中医杂志,1996:23(12):533.
[49]余江毅,熊宁宁,余承惠等.慢性肾病瘀血与湿热病理的临床和实验研究[J].中医杂志,1995;22(2):91.
[50]邓银泉.慢性肾炎辨证论治与血浆纤维结合蛋白的关系[J].辽宁中医杂志,1998;25(3):103.
[51]吴仕九,廖礼兵.湿热证大鼠肾内髓及尿液中水通道蛋白AQP2含量的变化[J].中国中医药科技,2003;10(1):4.
[52]朱绍琼,金红,谭泽民等.小儿肾性水肿中医辨证分型与血清学指标的关系初探[J].中华实用中西医杂志,2004;4(17):351.
[53]张光荣,徐友妹,皮持衡等.肾病综合征辨证分型与血总纤容活力、超氧化物歧化酶及血清白蛋白的关系[J].中国中西医结合杂志,1994;14(5):274.
[54]刘慰祖,陈以平,徐篙年等.肾小球肾炎患者补体旁路途径活性的测定及中药治疗前后的变化[J].中西医结合杂志,1986;6(4):210.
[55]熊宁宁,徐长照.家兔肾炎湿热模型的实验研究[J].辽宁中医杂志,1991;(4):42.
[56]刘宏伟.原发性肾小球疾病肾小球内补体成分测定与中医辨证分型的关系[J].辽宁中医杂志,1993;(3):1.
[57]李俊彪,莫穗林,朱雅宜.丹芍汤提高阴虚湿热型慢性肾炎患者红细胞免疫功能的临床研究[J].南京中医药大学学报,1996;12(2):18.
[58]盛梅笑,孙伟,贾宁人等.肾炎湿热证血清sICAM-1变化的临床观察[J].辽宁中医杂志,2003;30(11):891.
[59]张红梅,陈雪功,王望九等.慢肾蛋白停防治实验性慢性肾炎湿热证及对白细胞Fc 受体的影响[J].中国中西医结合急救杂,2004;11(1):34.
[60]朱辟疆,刘永平,田军民等.慢性肾小球疾病湿热证T淋巴细胞亚群及IL-2,sIL-2R的改变[J].中国中医药科技,1999;6(3):148.
[61]朱辟疆,施荣华,刘记平.慢性肾小球疾病湿热证血浆及尿白介素-6的改变[J].浙江中西医结合杂志,1999;9(2):75.
[62]朱辟疆,韦先进,江丽萍等.慢性肾小球疾病尿细胞因子改变及其与中医证型的关系[J].现代中西医结合杂志,2005;14(1):20.
[63]余江毅,熊宁宁,余承惠等.慢性肾病瘀血与湿热病理的临床和实验研究[J].中医杂志,1995:22(2):91.
[64]王付民.慢性肾小球肾炎病理类型与中医分型相关性研究[J].辽宁中医杂志,1994;21(9):392.
[65]陆军,周易谦,崔爱东.成人原发性肾病综合征的中医辨证与病理类型的关系[J].实用中西医结合杂志,1998;11(10):863.
[66]阮诗玮,郑敏麟,王智等.IgA肾病湿热证与肾穿刺活检病理组织关系的临床研究[J].中国中西医结合肾病杂志,2003;4(10):583.
[67]孙伟,曾安平,严志林等.湿热病邪与慢性肾病关系探讨[J],中医研究,2000;13(1):37.
[68]侯安会,王磊.肾病湿热探讨[J].黑龙江中医,2000;(1):5.
[68]傅文录.时振声辨治肾病湿热证经验[J].中医研究,1995;8(3):24.
[70]卢远航.以湿热论治肾病综合征191例[J].陕西中医,1998;19(10):439-440.
[71]第二届全国中医肾病学术会议[J].陕西中医,1988;(1):4.
[72]方小南.龙胆泻肝汤加减治疗难治性'肾病综合征18例疗效观察[J].中国中医基础医学杂志,2002;8(8):60.
[73]周玉来.中西医结合治疗湿热型难治性肾病综合16例[J].中医研究,2002;15(3):37.
[74]谢惠芬,植金川,魏彦国.中西医结合治疗原发性肾病综合征105例[J].陕西中医,1994;15(4):152.
[75]林鹤和,曹康永,董建华等.肾病综合征[M].北京:中国中医药出版社,1992:77.
[76]刘建国.中西医结合治疗难治性肾病的良方妙法[M].北京:中国医药科技出版社,2000:138.
[77]程星.辨证分型治疗肾病等50例[J].福建中医药,1987;(1):18.
[78]朱辟疆.滋阴活血解毒利湿中药治疗难治性肾病综合征70例观察[J].中西医结合杂志,1989:(2):104.
[79]王钢.肾炎合剂Ⅱ号治疗原发性肾病综合征77例临床疗效总结[J].江苏中医,1993;14(4):10.
[80]何小萍.中西医结合治疗原发性肾病综合征48例[J].河南中医药学刊,1998;13(5):35.
[81]谢桂权,高颍,冯天保等.清热利湿法治疗肾病综合征湿热证45例疗效观察[J].新中医,2007;39(10):58-87.
[82]Wasinger VC,Cordwell SJ,Cerpa-Poljak A.et al.Progeress withgenne-product mapping of the Mollicutes:Mycoplasma genitalium[J].Electrophoresis,1995,16(7):1090-1094.
[83]R.Constellations in a cellular universe[J].Nature,2003,422:115
[84]金光亮.证候基因组学和证候蛋白质组学浅论[J].中国医药报,2003;16(8):332-335
[85]Farrell PH,High resolution two-dimensional eletrophoresis ofproteins.Biol Chem,1975:250:4007.
[85]Klose J,Kobalz U.Two dimensional eletrophoresis of proteins anupdated proteocol and implications for a function analysia of thegenome.Electrophoresis,1995:16:1034.
[87]Molloy MP.T wo-dimensional eletrophoresis of membrane proteins using immobilized pH gradients.Anal Biochem,2000;280:1.
[88]Fey SI,Larsen PM.2D or not 2D.Two dimensional eletrophoresis.CurrOpin Chem Biol,2001;5:26.
[89]Klein E,Klein JB,Thongboonkerd V.Two-dimensional eletrophoresis a fundamental tool for expression proteomics studies.Contrib Nephrol,2004:141:25.
[90]Gioraianni F,Deside rio DM,Beranova-Gioorgianni S Proteome analysis using isoelectric focusing in immobilized pHguadient gels followed by mass apectrometry.Electrophoresis,2003;24:253.
[91]GorgA,Wejss W,DunnMJ Current two-dimensional electrophoresis technology for proteomics.Protemics,2004:4(12):3665.
[92]GorgA,BoguthG,KopfA.Sample prefractionation with Sephadex Isoelectric focusingpriortonarrow pH range two dimensional gels.Proteomics,2002;2(12):1652-1657.
[93]GorgA,ObermaierC,BoguthG.The current state of two-dimension Electrophoresiswith immobilized pH gradients.Electrophoresis,2000:21(6):1037-1053.
[94]RabilloudT.Silver staining of 2D electrophoresisgels.Methods MolBio,1999:112:297-305.
[95]MatsuiNM.Staining of preparative 2Dgels:Coomassie blue andimidazole-zincnegative staining.Methds MolBio,1999:112:307-311.
[96]LinkAJ.Auto radiographyof 2D gels.Methods MolBio,1999:112:285-290.
[97]WaterborgJH,MatthewsHR.Fluorography of polyacryla midege lscontainig tritium.Methods Mol Bio,1994:32:163-167.
[98]Lopez MF,Berggren K,ChernokalskayaE.A comparison of silver stainAnd SYPROR ubyProtein Gel Stain with respect toproteindetection intwo —dimension algels and identification by peptide mass profiling.Electrophoresis,2000;21(17):3673-3683.
[99]LopezMF,KristalBS,ChernokalskayaE.High-through put profiling of The mitochondrial proteome using affinity fractionation and automation.Electrophoresis,2000;21(16):3427-3440.
[100]Brown RS,Lennon JJ.Mass resolution improvement by incorporation of pulsed ion extraction in a matrix-assisted laser desorption/ionization linear time-of-flight mass spectrometer [J].Anal Chem,1995,67(13):1998-2003.
[101]Wilkes JG,Zarrin F,Lay JO JR,Vestal ML.Particle size distribution is not the major factor explaining variable analyze transmission efficiency in liquid chromatography/particle beam/mass spectrometry [JJ.Rapid Commun Mass 1995,9(2):133-137.
[102]Podtelejnikov A,Mann M.Delayed extraction improves specificity in database searches by matrix-assisted laser desorption/ionization peptide maps[J].Rapid Commun Mass Spectrom,1996,10(11):1371-1378.
[103]Vogeser M.Liquid chromatography-tandem mass spectrometry application in the clinical laboratory [J].Clin Chem Lab Med,2003,41(2):117-126.
[104]Smyth WF,Brooks PA.Critical evaluation of high performance liquid chromatography-electrospray ionisat ion-mass spectrometry and capillary electrophoresis-electrospray-mass pectrometry for the detection and determination of small molecules of significance in clinical and forensic science [J].Electrophoresis,2004,25(10-11):1413-1446.
[105]Verentchikov AN,Ens W,Standing KG.Reflecting time-of-flight mass pectrometer with an electrospray ion source and orthogonal extraction [J].Anal Chem,1994,66(1):126-133.
[106]Li J,Wang C,Kelly JF,Harrison DJ,Thibault P.Rapid and sensitive separation of trace level protein digests using microfabricated devices coupled to a quadrupole—time-of-flight mass spectrometer [J].Electrophoresis,2000,21 (1):198-210.
[107]Kristensen DB,Imamura K,Miyamoto Y,Yoshizato K.Mass spectrometric approaches the characterization of proteins on a hybrid quadrupole time-of-flight (Q-T0F)mass spectrometer [J].Electrophoresis,2000, 21(2):430-439.
[108]Colsch B,Afonso C,Popa I,Portoukalian J,Fournier F,Tabet JC,Baumann N.Characterization of the ceramide moieties of sphingog]ycolipids from mouse brain by ESI-MS/MS:identification of ceramides containing sphingadienine[J].J Lipid Res,2004,45(2):281-286.
[109]GovorunVM,etal.Proteomic technologies in modern biomedical science.Biochemistry(Moscow),2002:67(10):1109.
[110]叶雪清,曾淑华,张宛明等.月经失调的八纲辨证与植物神经系统功能关系的研究[J].中西医结合杂志,1984,4(4):198.
[111]叶雪清,杨少文,李安,等.阳虚患者植物神经系统功能、甲微循环和血液流变学的改变及相互作用[J].中西医结合杂志,1989,9(10):618.
[112]陆启滨,夏桂成,陈丹华等.159例绝经前后诸证阴虚火旺型患者的植物神经功能观察[J].上海中医药杂志.1990,(2):12.
[113]全建峰,吴晓康,孙晓虹.肾阴虚证患者的血清免疫球蛋白G、A、M及补体C_3、C_4相关性研究[J].现代中医药,2004,5(2):53-54.
[114]蔡宛如,汤军,徐志瑛等.肺心病痰热型与痰热伤阴型的免疫学指标观察[J].中国医药学报,2000,15(2):43.
[115]秦路平,张家庆.蛇床子香豆素对肾阳虚模型大鼠腺垂体-肾上腺皮质轴功能的影响[J].中国中西医结合杂志,1997,17(4):227-229.
[116]樊蔚虹,岳广欣,任小巧,等.肝肾阴虚证大鼠下丘脑垂体-甲状腺轴的变化及中药对其调节作用[J].中国中医药信息杂志,2001,8(10):21.
[117]丘瑞香,吴国珍,金明华.性激素对肾虚患者阴阳平衡的调节作用[J].中国中医基础医学杂志,1999,5(3):46.
[118]薛沙,汤学军.右归丸对肾阳虚动物模型血液微量元素含量的影响[J].中国中医药科技,2002,7(3):168-169.
[119]申维玺,孙燕,刘晓燕,等.用现代医学理论阐明肾阴虚证的本质和发病学机制[J].医学与哲学,2005,26(11):67-69.
[120]陈小野.证候实质研究中弱特异性的正面观[J].医学与哲学,1995,16(6):311-313.
[121]刘为民.中医证候学研究与证候蛋白质组学[J].中医药学报,2003;(31):3-7.
[122]余宗阳,杜建.蛋白质组学与中医证候实质研究[J].中国中西医结合杂志,2004;24(9):844-846.
[123]申维玺.论中医“证本质“的科学内涵[J].中国中医基础医学杂志,2001;7(6):410.
[124]申维玺,孙燕.论中医药的化学本质是蛋白质和肽及证本质的分子标准[J].中国 中西医结合杂志,1999;19(11):696.
[125]申维玺,孙燕.用分子生物学理论阐释阴虚证的本质[J].医学研究通讯,1998;27(8):1.
[126]刘为民.中医证候学研究与证候蛋白质组学[J].中医药学报,2003;31(3):1.
[127]邱德有,吴小红,黄璐琦.现代生命科学技术对中医药发展的影响[J].世界科学技术,2001;3(2):12.
[128]TONGE R,SHAW J,MIDDLETON B,et al.Validation and development of Fluorescence two-dimensional differential gelelectrophoresis proteomics technology[J].Proteomies,2001;1(3):377-396.
[129]马增春,高月.复方丹参片对冠心病患者血浆蛋白影响的蛋白质组学研究[J].中国中药杂志,2006;31(9):766-769.
[130]钟小兰,吕志平,钱令嘉等.束缚所致肝郁证动物模型肝组织蛋白质组的差异表达研究[J].中医杂志,2006;47(5):371-373.
[131]刘丽丽,马增春,王宇光等.四物汤对环磷酰胺致血虚证小鼠骨髓蛋白质组的影响[J].中国中药杂志,2006;31(14):1172-1175.
[132]卢德赵,沃兴德,施孟如等.激素型肾阳虚动物肝线粒体蛋白质组与能量代谢相关性[J].中国生物化学和分子生物学报,2005:21(6):807-814.
[133]王海彬,刘建仁,樊粤光等.中药治疗大鼠去卵巢骨质疏松症的蛋白质组学分析[J].四川中医.2006;24(8):9-13.
[134]张莺,陈泽奇,钟广伟.平肝潜阳法对高血压模型大鼠下丘脑蛋白质表达的影响[J].广州中医药大学学报,2008;25(4):325-331.
[135]杨波,梁清华,蔡颖等.痹肿消汤干预胶原诱导性关节炎大鼠滑膜病变的蛋白质组学研究[J].中国临床康复,2006;10(15):74-78.
[136]郭平,马增春,李鹰飞等.四物汤对放射线致血虚证小鼠骨髓蛋白质表达的影响[J].中国中药杂志,2004;29(9):893-896.
[137]吴伟康,李劲平.四逆汤抗心肌缺血作用的相关蛋白谱研究[J].中国病理生理杂志,2005:21(3):506-510.
[138]姜楠,霍海如,李兰芳等.桂皮醛对发热大鼠下丘脑蛋白质组双向凝胶电泳分析[J].中药药理与临床,2003:19(6):11-13.
[139]张萃,王培训,周联等.活血化瘀中药对内毒素诱导THP21细胞增殖及蛋白质组的影响[J].中国免疫学杂志,2006:22(7):665-670.
[140]宋元英,王忠,曲迅等.中药不同组分对小鼠缺血脑组织蛋白表达谱的影响[J].中国中西医结合杂志,2006;26(6):526-528.
[141]张萃,王培训,周联等.活血化瘀中药对内毒素诱导THP-1细胞增殖及蛋白质组的影响[J].中国免疫学杂志,2006;22:662-670.
[142]上海第二医科大学附属仁济医院中医内科肾病组.成人肾病综合征267例的治疗体会[J].新医药学杂志,1978;(3):22.
[143]孙伟,曾安平,严志林等.湿热病邪与慢性肾病关系探讨[J].中医研究,2000;13(1):37.
[144]朱学云,钱卫东.高脂血症中医药研究进展[J].江苏中医,1998;19(6):46-471.
[145]谢桂权.中医药治疗慢性肾炎蛋白尿七法[J].新中医,1986;19(2):28-30.
[146]Sophia N,Lavrendadou,Margarita Hadzopoulou-Cladaras,Dmitris Kardassis and Vassihs I.Zannis[J].Biochemistry,1999;38:964-975.
[147]Weisgraher,Fmchart J C,Dufiez P.Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism[J].Drugs Today,2006;42(1):39-64.
[148]Woltje M,Tschoke B,von Bulow V,et al.CCAAT enhancer bindinprotein beta and hepatocyte nuclear factor 3beta are necessary ansufficient to mediate dexamethasone-induced up-regulation of alpha2 HS-glycoprotein/fetuin-A gene expression[J].J MEndocrinol,2006;36(2):261-277.
[149]Mathews ST,Chellam N,Srinivas PR,et al.Alpha(2)-HSG,a specifinhibitor of insulin receptor autophosphorylation,interacts with thinsulin receptor[J].Mol Cell Endocrinol,2000;164(1-2):87-98.
[150]Stefan N,Hennige AM,Staiger H,et al.Alpha2-Heremans-Schmid glycoprotein/fetuin-A is associated with insulin resistan ce and faaccumulation in the liver in humans[J].Diabetes Care,2006;29(4853.857.
[151]Mathews ST,Singh GP,Ranalletta M,et al.Improved insulsensitivity an d resistance to weight gain in mice null for the Ahsgone[J]1.Diabetes,2002;51(8):2450-2458.
[152]l Mathews ST,Rakhade S,Zhou X,et al.Fetuin.null mice arprotected against obesity and insulin resistance associated with agin[J].Biochem Biophys Res Commun,2006;350(2):437-443.
[153]Price PA,Thomas GR,Pardini AW,et al.Discovery of a higmolecular wei ght complex of calcium,phosphate,fetuin and matrigamma -carboxyglutamic acid protein in the serum of etidronatetreated rats[J].J Biol Chem,2002;277(6):3926-3934.
[154]Heiss A,DuChesne A,Denecke B,et al.Structural basis calcification inhibition by alpha 2-HS glycoprotein/fetuin-A Formation of colloidal.calciprotein particles[J].J Biol Chem,2003;278(15):13333-13341.
[155]Szweras M,Liu D,Partridge EA,et al.2-HS glycoprotein/fetuin,atransforming growth factor-lB/bone morphogenetic protein antagonist,regulates postnatal bone growth and remodeling[J].J Biol Chem,2002:277(22):19991-19997.
[156]Gangneux C,Daveau M,Hiron M,et al.The inflammation-induced down-regulation of plasma Fetuin-A(2HS-Glycoprotein) in liverresults from the loss of interaction between long C/EBP isoforms attwo neighbouring binding sites[J].Nucleic Acids Res,2003:31(20):5957-5970.
[157]Georgina Reh,Bibiana Nerli,Guillermo Pico.Isolation of alpha-l-antitrypsin from human plasma by partitioning in aqueous biphasic systems of polyethyleneglycol-phosphate[J].Joumal of Chromatography B,2002:780:389-396.
[158]Hyun Kyu Song.Crystal structure of uncleavedet I-antitrypsin reveals the conformation of its inhibitory reactive loop[J].FEBS Letters,1995;377:150-154.
[159]hezdey J,et al.Treatment of osteocarcinama with alpha-l-anti-trypsin or secretory leucocyte proteinaso inhibitor[M]USP6670325,Dec 30,2003;30(10):56-59
[160]董淑兰,刘伟龟,张秋业等.肾病综合征病儿血清α_1-抗胰蛋白酶的变化及临床意义[J].青岛医学院学报,1992;28(3):28-29.
[161]Brown WM.rAAt(inhaled) Arriva/Hyland[J].lmmuno.Curr Opin Mol Ther,2006:8(1):76-82.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |